Praktikertjänst-backed Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.
Aprea Therapeutics, a US-based cancer drug developer backed by healthcare provider Praktikertjänst, has raised $85m yesterday in an initial public offering on the Nasdaq Global Select Market.
The company issued approximately 5.7 million shares on Tuesday priced at $15 each, in the middle of the IPO’s $14 to $16 range. Its shares rose by more than a third to close at $20.50 on its first day of trading yesterday, giving it a market cap of about $408m.
Spun out…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
